25 October
2024
Provexis
plc
('Provexis' or the
'Company')
Result of AGM
Provexis, the business that develops,
licenses and sells the proprietary, scientifically-proven
Fruitflow® heart-health functional food ingredient, announces that
at the Company's Annual General Meeting, held earlier today, all
resolutions were duly passed. The proxy
votes received from shareholders on each resolution are set out
below.
|
Resolutions
|
Votes for
*
|
%
|
Votes
against
|
%
|
Votes total
**
|
Votes
withheld
***
|
|
Resolution
1
|
392,370,219
|
99.99%
|
56,746
|
0.01%
|
392,426,965
|
155,249
|
|
Resolution
2
|
388,990,993
|
99.09%
|
3,581,721
|
0.91%
|
392,572,714
|
9,500
|
|
Resolution
3
|
385,785,158
|
98.27%
|
6,775,056
|
1.73%
|
392,560,214
|
22,000
|
|
Resolution
4
|
351,188,841
|
90.18%
|
38,221,373
|
9.82%
|
389,410,214
|
3,172,000
|
|
Resolution
5
|
384,515,794
|
98.74%
|
4,906,920
|
1.26%
|
389,422,714
|
3,159,500
|
|
Resolution
6
|
385,637,205
|
99.03%
|
3,773,009
|
0.97%
|
389,410,214
|
3,172,000
|
|
Resolution
7
|
392,435,158
|
99.96%
|
137,556
|
0.04%
|
392,572,714
|
9,500
|
|
*
|
Includes discretionary
votes
|
|
**
|
Total votes cast do not include
withheld votes
|
|
***
|
A vote withheld is not a vote in law
and is not counted in the calculation of the proportion of votes
'For' or 'Against' any of the resolutions
|
For further information please
contact:
|
Provexis plc
Dawson Buck, Chairman
Ian Ford, CEO
|
Tel: 07490
391888
enquiries@provexis.com
|
|
Allenby Capital Limited
Nick Naylor / Liz Kirchner / Lauren
Wright
|
Tel: 020 3328
5656
|
Notes for editors
About Provexis plc
AIM quoted Provexis is focused on the
development, licensing and sales of its proprietary,
scientifically-proven Fruitflow® heart-health functional food
ingredient.
Fruitflow is a natural, breakthrough ingredient
that helps with platelet aggregation. This helps promote normal
blood flow and circulation, which in turn benefits cardiovascular
health. Fruitflow helps the platelets to circulate freely and
smoothly throughout your blood, without sticking to one another or
to the blood vessels themselves. Freely flowing blood helps reduce
stress on your cardiovascular system.
Fruitflow is a highly concentrated form of
bioactives which is lycopene-free and contains over 30 known
anti-platelet compounds. Published clinical studies have shown that
Fruitflow works to maintain healthy blood flow in a similar way to
75mg aspirin but with a milder and reversible action; Fruitflow has
a similar antiplatelet effect to a single dose of aspirin - but
when taken daily, it has none of aspirin's side effects.
The science behind Fruitflow has been validated
by leading peer review publications and regulatory authorities.
Fruitflow is the only natural antiplatelet to have a health claim
approved by the European Food Safety Authority, stating that 150mg
of Fruitflow 'helps maintain normal platelet aggregation, which
contributes to healthy blood flow'.
Fruitflow has a number of specific health
benefits which have been reflected in separate patent filings for
the use of Fruitflow in:
·
mitigating exercise-induced inflammation;
·
managing blood pressure;
·
protecting against the adverse effects of air pollution on
the body's cardiovascular system. Laboratory work has shown that
Fruitflow can reduce the platelet activation caused by airborne
particulate matter, such as that from diesel emissions, by
approximately one third; and
·
conferring health benefits in modulating the gut microbiome
of humans, to include a reduction in TMAO, following the completion
of a successful human study which is further detailed here
www.dsm.com/human-nutrition/en/talking-nutrition/press-releases/2023-01-20-new-study-reveals-dsms-fruitflow-activates-gut-heart.html.
Provexis sells a high quality dietary supplement
product containing Fruitflow and Omega-3 from its website
www.fruitflowplus.com
on a mail order basis. The product is also available to
purchase from Amazon.co.uk.
Provexis has been working with BYHEALTH, a
circa £2bn listed Chinese dietary supplement business, for more
than eight years to support the planned launch of a number of
Fruitflow based products in the Chinese market. Clinical studies
conducted in China are typically required to obtain the necessary
regulatory clearances in China, and a significant investment in
eight separate Fruitflow studies has been undertaken at BYHEALTH's
expense. Completed studies have shown excellent results in use for
Fruitflow, and they provide strong evidence for the efficacy of
Fruitflow on platelet function.
The Chinese regulatory system for functional
health food ingredients, such as Fruitflow, is governed by the
State Administration for Market Regulation (the 'SAMR') and it is
based on a defined list of permitted health function claims which
brand owners are permitted to use on product labels.
In August 2023 the Company was delighted to
report that BYHEALTH had submitted: i) the first application for a
new permitted health function claim and ii) some related product
registration applications.
The significance of these major developments
for Fruitflow in China is further outlined here
www.nutraingredients-asia.com/Article/2023/09/05/china-set-to-approve-new-function-claims-for-health-foods#.
BYHEALTH has noted that it has been working on the project since
2015, with 'tens of millions of funds' (RMB) invested by BYHEALTH
in the research and development work.
Provexis was founded in 1999 and is
headquartered in Reading, Berkshire. Provexis' shares are traded on
the AIM market of the London Stock Exchange under the ticker symbol
PXS.
For further information, please visit
www.provexis.com
and www.fruitflowplus.com.
